These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9220214)

  • 1. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Clin Ther; 1997; 19(3):498-506. PubMed ID: 9220214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
    Sramek JJ; Hong WW; Hamid S; Nape B; Cutler NR
    Depress Anxiety; 1999; 9(3):131-4. PubMed ID: 10356651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
    Sramek JJ; Tansman M; Suri A; Hornig-Rohan M; Amsterdam JD; Stahl SM; Weisler RH; Cutler NR
    J Clin Psychiatry; 1996 Jul; 57(7):287-91. PubMed ID: 8666569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
    Davidson JR; DuPont RL; Hedges D; Haskins JT
    J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P; Rouillon F; Pouget D
    Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.
    Bourin M; Malinge M
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):567-75. PubMed ID: 8588056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing.
    Pohl RB; Feltner DE; Fieve RR; Pande AC
    J Clin Psychopharmacol; 2005 Apr; 25(2):151-8. PubMed ID: 15738746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder.
    Lader M; Scotto JC
    Psychopharmacology (Berl); 1998 Oct; 139(4):402-6. PubMed ID: 9809861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
    Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of buspirone and diazepam in generalized anxiety disorder.
    Jacobson AF; Dominguez RA; Goldstein BJ; Steinbook RM
    Pharmacotherapy; 1985; 5(5):290-6. PubMed ID: 2866493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam.
    Strand M; Hetta J; Rosen A; Sörensen S; Malmström R; Fabian C; Marits K; Vetterskog K; Liljestrand AG; Hegen C
    J Clin Psychiatry; 1990 Sep; 51 Suppl():40-5. PubMed ID: 2211567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.
    Peoples AR; Bushunow PW; Garland SN; Heckler CE; Roscoe JA; Peppone LL; Dudgeon DJ; Kirshner JJ; Banerjee TK; Hopkins JO; Dakhil SR; Flannery MA; Morrow GR
    Support Care Cancer; 2016 Mar; 24(3):1339-47. PubMed ID: 26329396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder.
    Cutler NR; Hesselink JM; Sramek JJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):447-63. PubMed ID: 7915845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
    Laakmann G; Schüle C; Lorkowski G; Baghai T; Kuhn K; Ehrentraut S
    Psychopharmacology (Berl); 1998 Apr; 136(4):357-66. PubMed ID: 9600581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial.
    Chen P; Zhu H; Ning Y; Yin D; Jia H
    Trials; 2020 Mar; 21(1):266. PubMed ID: 32171323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buspirone in the management of major depression: a placebo-controlled comparison.
    Fabre LF
    J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone in depressed outpatients: a controlled study.
    Rickels K; Amsterdam J; Clary C; Hassman J; London J; Puzzuoli G; Schweizer E
    Psychopharmacol Bull; 1990; 26(2):163-7. PubMed ID: 2236452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder.
    Enkelmann R
    Psychopharmacology (Berl); 1991; 105(3):428-32. PubMed ID: 1798836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled comparison of buspirone and oxazepam in generalized anxiety.
    Ansseau M; Papart P; Gérard MA; von Frenckell R; Franck G
    Neuropsychobiology; 1990-1991; 24(2):74-8. PubMed ID: 2134114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.